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ABSTRACT 
This study was conducted to evaluate the effect of collagen matrix implant on pterygium recurrence 
compared with a control group following pterygium removal surgery. Following informed consent, twenty 
eyes of 20 patients (females = 13, males = 7, aged 23–67 years) were randomly allocated into two equal 
groups. Pterygia of all patients were excised using the bare sclera technique; however, for patients in the 
intervention group a 1×2 mm collagen matrix graft (iGen™) was implanted subconjunctivally. Patients were 
followed up for recurrence and complications within six months. Results revealed that only two eyes in the 
control group and one eye in the intervention group developed recurrence (p=0.50); no dellen formation 
was observed. In conclusion, the use of biodegradable collagen matrix implants (iGen™) following 
pterygium excision seems to be associated with a lower risk of recurrence; however, the statistical 
difference between groups was not significant. Further studies with adequate sample size are 
recommended. 
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INTRODUCTION 
Pterygium is a common disorder in many parts of the 
world, with reported prevalence rates ranging from 0.3 
to 29%. Epidemiological studies have proposed an 
association with chronic exposure to sunlight and an 
increased geographical prevalence within a peri-
equatorial ‘pterygium belt’ region (1). While there is 
currently no universal consensus for grading of 
pterygium, one of the current methods has graded 
pterygia as follows: stage 0: pinguecula posterior to the 
limbus; stage 1: the pterygium is restricted to the limbus; 
stage 2: the pterygium only marginally invades the 
cornea; stage 3: the pterygium is between the limbus and 
pupillary margin; and stage 4: the pterygium is central to 
the pupillary margin (2). 
  While pterygium excision is often combined with 
various adjunctive measures to prevent its recurrence 
(1), this is still the most common post-surgical 
complication and represents a significant surgical 
problem. Numerous techniques have been attempted to 
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reduce localized fibrovascular activity and the overall 
rate of recurrence; these include, β-irradiation, 
conjunctival and limbal auto-grafting, antimitotic drugs 
and amniotic membrane transplantation (3). 
  In recent years, a novel bioengineered product has been 
suggested and has shown promising outcomes in animal 
models (4). Biodegradable collagen matrix implants 
(iGen™) are porous scaffolds that can encourage a 
regenerative and non-scarring wound healing process 
without the use of medications. Its manufacturer has 
described its use not only for trabeculectomy, but also 
for other ophthalmic surgeries such as pterygium 
removal, oculoplastic surgery and veterinary surgery (5). 
The principle of the iGen™ collagen implant is to 
stimulate random growth of fibroblasts, which 
subsequently leads to normal wound healing. The iGen™ 
scaffold’s porous structure can work as a reservoir, a 
buffering system, and also as a controlled drainage 
solution. It randomizes the growth of myofibroblasts and 
creates a novel physiological environment between the 
anterior chamber and subconjunctival space of the eye. It 
maintains the physiological barrier by regeneration, 
which then maintains both the function of the bleb and 
normalizes the dynamic aqueous balance to create a safe 
conjunctival system. It also prevents scar formation 
inside the wound by guiding fibroblasts to grow 
randomly throughout the matrix pores (4,5). In this 
study, we aimed to evaluate post operation 
complications of iGen™ in pterygium surgery. 
 
METHODS 
In this prospective study we studied 20 eyes of 20 
patients with pterygium who had been referred to Al-
Zahra Ophthalmologic Hospital, Zahedan, Iran between 
January 2011 and March 2012. Patients were randomly 
assigned equally to either the intervention or control 
groups. Patients were included if they had pterygium in 
stage 3 measuring 3 mm and 2 mm in horizontal and 
vertical diameters, respectively, which were associated 
with recurrent red eye, foreign body sensation, active 
vascularized advancing head, decreased visual acuity due 
to involvement of visual axis, and cosmetic problems. 
Exclusion criteria included patients who had any history 
of ocular surgery including pterygium removal, presence 
of symblepharon, evidence of systemic diseases (e.g. 
diabetes, AIDS, hepatitis, etc.), past history of atopy and 
hypersensitivity, or traumatic injury to the anterior 
segment of the eye leading to surgical repair. This study 
was approved by ethical committee of Zahedan 
University of Medical Sciences, Zahedan, Iran and proper 
informed consents were obtained from patients. 
  All patients underwent surgery using the bare sclera 
method. Following administration of topical and local 
anesthesia and placing the speculum in situ, the 
pterygium was removed in a sterile fashion. Prior to 
suturing the conjunctiva using 10-0 nylon or 7-0 Vicryl™, 
a 1×2 or 2×2 square millimeter porous collagen matrix 
(iGen™, Life Spring Biotech Co, Taiwan) was implanted 
beneath the conjunctiva of those in the intervention 
group. Twenty-four hours following surgery all patients in 
both groups received treatment with drops of 
ciprofloxacin and betamethasone four times a day for 1 
week’s duration. 
  Follow-up visits for evaluation of complications or 
recurrence were on the first day, first week, first month, 
third month and sixth month postoperatively. The 
presence of dellen was considered as a complication, and 
recurrence was defined as at least 1 mm regrowth of the 
conjunctival fibrovascular tissue toward the cornea in 
both vertical and horizontal diameters during the follow-
up time and, in such cases, its size was calculated from 
advancing edge in mm2 (6). Absence of recurrence 
and/or complications was considered as indicating the 
efficacy or safety of the procedure. Subsequently, 




Twenty eyes of 20 patients with unilateral or bilateral 
pterygium were enrolled (females = 13 females, males = 
7, aged 23–67 years). In the intervention group there was 
one patient who developed mild symptoms of recurrent 
inflammation, tearing, and foreign body sensation at the 
first month, which worsened in the third month following 
collagen implant with development of specified 
recurrence criteria. In the control group only two 
patients mentioned symptoms more prominently in the 
third month following surgery with recurrence of 
pterygium noted on slit lamp examination. However, 
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there were no complications such as dellen formation in 




We compared the effects of subconjunctival implantation 
of a collagen matrix (iGen™) following pterygium removal 
by the bare sclera method in an intervention group with 
a control group who were treated solely with bare sclera 
method and found a higher rate of recurrence among the 
latter. The statistical difference, however, was not 
significant (p>0.05) and should be attributed to the small 
sample size and short duration of follow up. 
  Pterygium is one of the most common conjuctival 
disorders, especially evident in regions with high 
ultraviolet exposure and a dry climate (3,7) such as  
Zahedan in South East, Iran. 
  Despite the introduction of several techniques for 
treatment of pterygium, recurrence is still an 
ophthalmologic dilemma. The definition of pterygium 
recurrence, however, varies among studies. Most 
ophthalmologists define pterygium recurrence as 
regrowth of fibrovascular pterygium-like tissue crossing 
the limbus on to the cornea, fibrovascular recurrence to 
the same degree of corneal encroachment as the original 
lesion, or regrowth exceeding 1 mm onto the cornea (1). 
There are many options for wound closure after 
pterygium removal such as simple closure, rotational or 
sliding flap, free flap and/or limbal transplantation (7-9). 
In a non-randomized trial, Madrazo et al. deliberated the 
efficacy of a biodegradable collagen matrix implant 
(OculusGen®) following pterygium excision on 20 eyes, 
and followed up the patients for at least 3 months. They 
reported a pterygium recurrence rate of 5% without any 
complications or adverse effects (10). In general, 
biodegradable collagen matrix implants have been used 
safely following trabeculectomy and they seem to be 
used as alternating treatments with antimitotic drugs 
(5,11); however, there are few reports of their efficacy in 
preventing pterygium recurrence. One of the limitations 
in our study was the bare sclera technique used for 
pterygium removal as this technique is less commonly 
used. 
  In conclusion, the implantation of collagen matrix is a 
quick and easy technique, may be associated with lower 
rate of pterygium recurrence and subsequently may 
improve outcomes from the bare sclera method of 
surgery. Further studies with a larger sample size and 
longer duration of follow up are recommended to further 
explore this technique. 
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